Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Empros Pharma AB is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct art units. This distribution indicates that each of the company's current matters is being evaluated independently in different technical groups.
Carlos A Azpuru is the busiest examiner for the portfolio, with 1 pending office action. Given that there are multiple distinct examiners, the workload is divided such that each official oversees an action among the company's active patent applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
| AZPURU, CARLOS A | 1 | 83.8% | +10.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562765 | REDUCED REBOUND EFFECTS IN SUBJECTS TREATED FOR OVERWEIGHT OR OBESITY | AZPURU, CARLOS A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562761 | SYNERGISTIC EFFECTS ON WEIGHT LOSS, IMPROVED QUALITY OF LIFE AND REDUCED GASTRO-INTESTINAL SIDE EFFECTS WITH A COMPOSITION OF ORLISTAT AND ACARBOSE | STEVENS, MARK V | 126d overdue |
| 18562765 | REDUCED REBOUND EFFECTS IN SUBJECTS TREATED FOR OVERWEIGHT OR OBESITY | AZPURU, CARLOS A | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562761 | SYNERGISTIC EFFECTS ON WEIGHT LOSS, IMPROVED QUALITY OF LIFE AND REDUCED GASTRO-INTESTINAL SIDE EFFECTS WITH A COMPOSITION OF ORLISTAT AND ACARBOSE | STEVENS, MARK V | 1613 | §103DP | Non-Final OA | 126d overdue | Pending | Nov 20, 2023 |
| 18562765 | REDUCED REBOUND EFFECTS IN SUBJECTS TREATED FOR OVERWEIGHT OR OBESITY | AZPURU, CARLOS A | 1617 | DP | Final Rejection | — | Pending | Nov 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial